Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Elite Pharma Inc (ELTP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 65,349
  • Shares Outstanding, K 816,860
  • Annual Sales, $ 7,460 K
  • Annual Income, $ -3,670 K
  • 36-Month Beta 0.44
  • Price/Sales 8.66
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/08/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0770 +5.19%
on 10/15/18
0.0940 -13.83%
on 10/01/18
-0.0100 (-10.99%)
since 09/21/18
3-Month
0.0770 +5.19%
on 10/15/18
0.1289 -37.16%
on 08/06/18
-0.0225 (-21.74%)
since 07/20/18
52-Week
0.0560 +44.64%
on 10/27/17
0.1450 -44.14%
on 01/11/18
-0.0119 (-12.81%)
since 10/20/17

Most Recent Stories

More News
Elite Pharmaceuticals Files ANDA for Codeine and Acetaminophen Combo

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB: ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it has filed...

ELTP : 0.0810 (+1.25%)
Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB: ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today reported positive topline results...

ELTP : 0.0810 (+1.25%)
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2019 Financial Results on August 10, 2018

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB: ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that...

ELTP : 0.0810 (+1.25%)
Elite Pharmaceuticals Appoints Aqeel A. Fatmi, Ph.D. to Its Board of Directors

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB: ELTP) announced today the appointment of Aqeel A. Fatmi, Ph.D. to its Board of Directors. Dr. Fatmi qualifies as an independent director under...

ELTP : 0.0810 (+1.25%)
Elite Pharmaceuticals Receives FDA Approval for Generic Methadone Hydrochloride Tablets

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB: ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it received...

ELTP : 0.0810 (+1.25%)
New Research: Key Drivers of Growth for Bioheart and Elite Pharmaceuticals - Factors of Influence, Major Initiatives and Sustained Production

NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Bioheart Inc. (OTCQB: USRM) and Elite Pharmaceuticals Inc. (OTCQB:...

ELTP : 0.0810 (+1.25%)
USRM : 0.0305 (+2.35%)
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2018 Ended September 30, 2017

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results for the second quarter...

ELTP : 0.0810 (+1.25%)
CORRECTING and REPLACING - Elite Pharmaceuticals, Inc.

In a release issued earlier today by Elite Pharmaceuticals, Inc. (OTCQB:ELTP), please note in the headline the conference call date should be "November 10" rather than "September 10" as previously issued....

ELTP : 0.0810 (+1.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ELTP with:

Key Turning Points

2nd Resistance Point 0.0851
1st Resistance Point 0.0831
Last Price 0.0810
1st Support Level 0.0790
2nd Support Level 0.0769

See More

52-Week High 0.1450
Fibonacci 61.8% 0.1110
Fibonacci 50% 0.1005
Fibonacci 38.2% 0.0900
Last Price 0.0810
52-Week Low 0.0560

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar